(Q37483987)

20 August 2017

1 reference

title

Mode of action and clinical impact of VEGF signaling inhibitors (English)

1 reference

20 August 2017

Jens Soltau

1

1 reference

20 August 2017

Joachim Drevs

series ordinal

2

1 reference

20 August 2017

publication date

1 May 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

649-662

1 reference

Angiogenesis in cancer and other diseases

20 August 2017

cites work

1 reference

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

The implications of angiogenesis for the biology and therapy of cancer metastasis

21 January 2018

1 reference

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

The history of the angiogenic switch concept

21 January 2018

1 reference

Challenges for patient selection with VEGF inhibitors

21 January 2018

1 reference

The biology of vascular endothelial growth factor

21 January 2018

1 reference

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy

21 January 2018

1 reference

Vascular endothelial growth factor signaling pathways: therapeutic perspective

21 January 2018

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

21 January 2018

1 reference

Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing

21 January 2018

1 reference

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

21 January 2018

1 reference

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

VEGF receptor signaling in tumor angiogenesis

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

Vascular endothelial growth factor trap in non small cell lung cancer

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

Imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

21 January 2018

1 reference

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

21 January 2018

1 reference

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

21 January 2018

1 reference

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

21 January 2018

1 reference

The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells

21 January 2018

1 reference

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

21 January 2018

1 reference

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

21 January 2018

1 reference

The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies

21 January 2018

1 reference

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

Of mice and (wo)men: is this any way to test a new drug?

21 January 2018

1 reference

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma

21 January 2018

1 reference

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

21 January 2018

1 reference

Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines

21 January 2018

1 reference

Interleukin-12: biological properties and clinical application

21 January 2018

1 reference

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

21 January 2018

1 reference

Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells

21 January 2018

1 reference

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

21 January 2018

1 reference

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

21 January 2018

1 reference

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer

21 January 2018

1 reference

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

21 January 2018

1 reference

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

21 January 2018

1 reference

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

21 January 2018

1 reference

Angiogenic growth factors and hypertension

21 January 2018

1 reference

KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF

21 January 2018

1 reference

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas

21 January 2018

1 reference

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

21 January 2018

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.19

1 reference

20 August 2017

1 reference